Pharmacogenomics and Post-Operative Nausea and Vomiting
- Registration Number
- NCT03503292
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 92
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CYP2D6 rapid metabolizer Granisetron Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment CYP2D6 normal metabolizer Ondansetron Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
- Primary Outcome Measures
Name Time Method Episodes of Postoperative Vomiting 0-48 hours post bariatric surgery The total number count of post operative vomiting episodes were determined by nursing documentation or by treatment with rescue antinausea medication.
Episodes of Postoperative Nausea 0-48 hours post bariatric surgery The total number count of post operative nausea episodes were determined by nursing documentation or by treatment with rescue antinausea medication.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States